Pelvic organ prolapse (POP) is a common condition affecting women, often associated with bothersome symptoms, altered body image, and  significant negative impact on quality of life and sexual function. Sacrocolpopexy is widely regarded as the gold-standard surgical treatment for POP.
Robotic-assisted surgery (RAS) was approved by the Food and Drug Administration in 2000 and nowadays has gained substantial popularity across surgical specialties such as urology and gynecology due to its advantages, including three-dimensional visualization, enhanced magnification, improved precision, superior ergonomics, reduced hospital stay and transfusion requirements.
The Hugo™ Robotic-Assisted Surgery (RAS) system represents a novel platform; however, current evidence regarding  urogynecologic procedures remains limited, as most published studies have focused on radical prostatectomy. Key technological features of Hugo™ RAS system include an open console, a modular cart with independently positioned robotic arms, and artificial intelligence (AI)-assisted image processing.

This study presents a surgical video demonstrating a step-by-step robotic sacrocolpopexy performed using the Hugo™ RAS system.
The case involves a 63-year-old woman with a history of vaginal hysterectomy and anterior colporrhaphy in 2023, who arrived to the outpatient clinic with urinary hesitancy and symptomatic cystocele. On physical examination, a stage III anterior pelvic organ prolapse was identified according to the POP-Q classification.
Given the patient’s relatively young age and sexually active status, robotic sacrocolpopexy was selected as the gold standard surgical approach. The video details key procedural steps, including patient positioning, trocar placement, docking strategy, dissection of the sacral promontory, preparation of the anterior and posterior vaginal walls, mesh placement and fixation, and peritoneal closure.
Key intraoperative parameters and technical considerations are highlighted throughout the procedure.

The procedure was successfully completed without conversion to open surgery or conventional laparoscopy. Operative time including docking was 180 minutes, with an estimated blood loss of 50 mL. No intraoperative complications were observed.
Postoperative recovery was uneventful, and the patient was discharged on postoperative day 2. Early follow-up demonstrated satisfactory anatomical correction and symptoms improvement. The Hugo™ RAS system provided adequate visualization, excellent instrument dexterity, and notable ergonomic advantages.

Robotic-assisted sacrocolpopexy using  Hugo™ RAS system is a feasible and safe approach. The platform offers satisfactory surgical performance and may represent a valuable alternative in minimally invasive urogynecologic surgery. Further studies are warranted to assess long-term outcomes and to compare its effectiveness with other robotic platforms.